Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

globenewswire

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 – NEWSnet – News… as it used to be

More Press Releases

April 30, 2026

CHAI AI, Backed by CoreWeave and AMD, Hits $80M ARR with talks of $2.4B Valuation

April 30, 2026

First National Bank Alaska declares dividend for second quarter 2026

April 30, 2026

DGNX Investors Have Opportunity to Join Diginex Limited Fraud Investigation with the Schall Law Firm

April 30, 2026

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

CHAI AI, Backed by CoreWeave and AMD, Hits $80M ARR with talks of $2.4B Valuation

First National Bank Alaska declares dividend for second quarter 2026

DGNX Investors Have Opportunity to Join Diginex Limited Fraud Investigation with the Schall Law Firm

University Bank Named a 2026 USA TODAY Top Workplace